Valeant Hires Morgan Stanley to Sell Dermatology Assets

  • Sale of Valeant’s Obagi, Solta could fetch up to $500 million
  • Process to sell assets set to kick off as early as this week

Valeant CEO Joe Papa Outlines Turnaround Plan

Valeant Pharmaceuticals International Inc. is working with advisers at Morgan Stanley as it weighs the sale of dermatology units Obagi Medical Products and Solta Medical to raise cash to reduce debt, according to people familiar with the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.